MeiraGTx Holdings plc
MeiraGTx Holdings plc (MGTX) Implied Volatility Current
MGTX implied volatility is 172%. IV Rank is 65%, placing current premiums in the middle of their 52-week range.
Read more
Tracking MGTX implied volatility helps you identify when options premiums on MeiraGTx Holdings plc are historically cheap or expensive, and where the best trades are hiding. MeiraGTx Holdings plc implied volatility reflects the market's expectation of future price movement: when MGTX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor MeiraGTx Holdings plc's implied volatility current levels in real time and filter for high-probability trades.
Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For MGTX, tracking metrics like MGTX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on MGTX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program.
The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where MGTX implied volatility sits today versus where it has been. Our scanner ranks MeiraGTx Holdings plc implied volatility against its historical range, surfaces extremes in MGTX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether MeiraGTx Holdings plc IV is rich or cheap — measure it, then act on it.
Implied Volatility
IV is slightly elevated - premiums are richer, leaning toward sellers.
As of September 18, 2026
Trade options with IV on your side
Track MGTX IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.
Start your 14-day free trial→